A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive
multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8
weeks.